1,721,028 research outputs found
Going Beyond Counting First Authors in Author Co-citation Analysis
Get PDFThe present study examines one of the fundamental aspects of author co-citation analysis (ACA) - the way co-citation
counts are defined. Co-citation counting provides the data on which all subsequent statistical analyses and mappings
are based, and we compare ACA results based on two different types of co-citation counting - the traditional type that
only counts the first one among a cited work's authors on the one hand and a non-traditional type that takes into
account the first 5 authors of a cited work on the other hand. Results indicate that the picture produced through this non-traditional author co-citation counting contains more coherent author groups and is therefore considerably clearer. However, this picture represents fewer specialties in the research field being studied than that produced through the traditional first-author co-citation counting when the same number of top-ranked authors is selected and analyzed. Reasons for these effects are discussed
Variations on the Author
Get PDF“Variations on the Author” discusses two of Eduardo Coutinho’s recent films (Um Dia na Vida, from 2010, and Últimas Conversas, posthumously released in 2015) and their contribution to the general question of documentary authorship. The director’s filmography is characterized by a consistent yet self-effacing form of authorial self-inscription: Coutinho often features as an interviewer that rather than express opinions propels discourses; an interviewer that is good at listening. This mode of self-inscription characterizes him as an author who is not expressive but who is nonetheless markedly present on the screen. In Um Dia na Vida, however, Coutinho is completely absent form the image, while Últimas Conversas, on the contrary, includes a confessional prologue that moves the director from the margins to the center of his films. This article examines the ways in which these works stand out in the filmography of a director who offers new insights into the notion of cinematic authorship
Appropriate Similarity Measures for Author Cocitation Analysis
Get PDFWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
Dispelling the Myths Behind First-author Citation Counts
Get PDFWe conducted a full-scale evaluative citation analysis study of scholars in the XML research field to explore just how different from each other author rankings resulting from different citation counting methods actually are, and to demonstrate the capability of emerging data and tools on the Web in supporting more realistic citation counting methods. Our results contest some common arguments for the continued
use of first-author citation counts in the evaluation of scholars, such as high correlations between author rankings by first-author citation counts and other citation
counting methods, and high costs of using more realistic citation counting methods that are not well-supported by the ISI databases. It is argued that increasingly available digital full text research papers make it possible for citation analysis studies to go beyond what the ISI databases have directly supported and to employ more
sophisticated methods
koamabayili/VECTRON-author-checklist: VECTRON author checklist
No full textWe have done our best to complete the author checklist relating to the use of animals in the hut study. Note that the objective for the hut study was to evaluate the IRS treatment applications for residual efficacy against Anopheles mosquitoes, including the local An. coluzzii mosquito population. Cows were only used to attract mosquitoes into the huts and no tests were carried out directly on the cows. The author checklist is intended for use with studies where experiments are carried out on animals, which is why we have had such difficulty in completing this for the hut study, as many of the questions do not relate to how the cows were used
Beta-blocker therapy after acute myocardial infarction with preserved ejection fraction : observational and clinical studies [Elektronisk resurs]
No full textBackground Cardiovascular disease, with its feared primary presentation of acute myocardial infarction (AMI), remains the leading cause of morbidity and mortality globally. Despite its routine use worldwide, the scientific evidence for beta-blocker therapy in patients with AMI and preserved left ventricular ejection fraction (LVEF) is surprisingly limited. Large, randomized trials are required to form a more solid base and to support recommendations. Methods and results Study I. An observational study linking data from multiple Swedish national registries assessed dose-dependent effects of beta-blockers on death from any cause and new AMI. A total of 97,575 patients with first-time AMI were included, where 33,126 (33.9%) patients were discharged with >50% of the target beta- blocker dose, and 64,449 (66.1%) patients with 50% of the target dose had a similar risk of the composite endpoint (HR, 1.03; 95% CI, 0.99 to 1.08; P = 0.18) compared with patients on Study II. A register-based, randomized, parallel, open-label, multicentre trial that evaluated the effect of routine initiation of beta-blocker treatment, in patients with AMI and preserved LVEF, in reducing the risk of death from any cause, or new AMI. The trial was performed at 38 centres in Sweden, one in Estonia, and six in New Zealand. From September 2017 through May 2023, 5020 patients were randomly assigned to either long-term beta-blocker treatment or no beta- blocker treatment. Baseline characteristics were well balanced between the two groups, the median age of the population was 65 years and 22.5% were women. Unadjusted Cox proportional hazards regression analysis showed that beta- blocker treatment did not decrease the risk of the composite endpoint, including death from any cause or new AMI, compared with no beta-blocker treatment (HR, 0.96; 95% CI, 0.79 to 1.16; P=0.64). Study III. A pre-specified substudy of the trial described in Study II, designed to evaluate the effect of beta-blockers on health-related quality of life (HRQoL) in patients with AMI and preserved LVEF. Responses to EQ-5D questionnaires were obtained at 6-10 weeks and 11-13 months after AMI. A total of 4,080 patients answered the forms, out of which 2,023 (49.6%) patients were randomized to beta-blockers. Baseline characteristics were similar to those in the main trial. The study reported results from intention-to-treat (ITT) and on-treatment analyses using the Wilcoxon rank sum test and adjusted ordinal regression analyses. The main outcome, median EQ-5D index score, did not differ between the groups at follow-up one (6-10 weeks after the AMI) (OR, 1.00; 95% CI, 0.89 to 1.13; P = 0.94). At the second follow-up (11-13 months after AMI), the results remained unchanged (OR, 1.02; 95% CI, 0.90 to 1.15; P = 0.78). The findings were robust in on-treatment analyses and across relevant subgroups. Study IV. A pre-specified substudy of the trial described in Study II, where conventional echocardiographic parameters and global longitudinal strain (GLS) measurements were obtained from routine echocardiographic examinations during the index hospitalization at four participating centres. The analysis addressed the question of whether or not GLS measurement in addition to LVEF improves outcome prediction. A likelihood ratio (LR) test between models adjusted for age, sex, hypertension, smoking, diabetes, previous AMI, and multivessel disease was used to compare LVEF and GLS as prognostic methods. A Cox regression model was used to evaluate the impact of beta-blocker treatment on the composite endpoint of death from any cause, or new AMI. A total of 1,436 patients (28.6% of the total population) were included. The LR test showed no significant difference (P = 0.56) when comparing the combination of GLS and LVEF to LVEF alone. The results were robust when adding beta-blocker randomization status as an independent variable. Conclusions This thesis provides new evidence that routine initiation of beta-blockers in patients with AMI and preserved LVEF does not decrease the risk of death from any cause, or new AMI, compared with no beta-blocker use. Even when complemented with more advanced echocardiographic measurements, no additive prognostic value regarding these endpoints was found. In addition, beta-blockers do not seem to affect HRQoL in this patient population. If beta-blockers are used, it appears that higher doses are not associated with improved cardiovascular outcomes. List of scientific papers I. Mars K, Wallert J, Held C, Humphries S, Pingel R, Jernberg T, Olsson EMG, Hofmann R. Association between ß-blocker dose and cardiovascular outcomes after myocardial infarction: insights from the SWEDEHEART registry. Eur Heart J Acute Cardiovasc Care. 2020. https://doi.org/10.1093/ehjacc/zuaa002 II. Yndigegn T, Lindahl B, Mars K, Alfredsson J, Benatar J, Brandin L, Erlinge D, Hallen O, Held C, Hjalmarsson P, Johansson P, Karlström P, Kellerth T, Marandi T, Ravn-Fischer A, Sundström J, Östlund O, Hofmann R, Jernberg T. Beta-Blockers after Myocardial Infarction and Preserved Ejection Fraction. N Engl J Med. 2024. https://doi.org/10.1056/NEJMoa2401479 III. Mars K, Humphries S, Leissner P, Jonsson M, Karlström P, Lauermann J, Alfredsson J, Kellerth T, Ravn-Fischer A, Erlinge D, Lindahl B, Yndigegn T, Jernberg T, Held C, Olsson EMG, Hofmann R. Effects of beta-blockers on quality of life and well-being in patients with myocardial infarction and preserved left ventricular function - a prespecified substudy from REDUCE-AMI. Eur Heart J Cardiovasc Pharmacother. 2024. https://doi.org/10.1093/ehjcvp/pvae062 IV. Mars K, Hofmann R, Jonsson M, Manouras A, Engvall J, Yndigegn T, Jernberg T, Shahgaldi K/ Sundqvist MG. The prognostic value of global longitudinal strain in patients with myocardial infarction and preserved ejection fraction - a prespecified substudy of the REDUCE-AMI trial. Eur Heart J Cardiovasc Imaging. 2025. https://doi.org/10.1093/ehjci/jeaf01
Author-wise bibliometric analysis based on entropy.
No full textAuthor-wise bibliometric analysis based on entropy.</p
Author Under Sail The Imagination of Jack London, 1893-1902
No full textIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Intro -- Title Page -- Copyright Page -- Dedication -- Contents -- Acknowledgments -- Introduction -- 1. Spirit Truth -- 2. From Absorption to Theatricality and Back Again -- 3. "I Will Build a New Present" -- 4. Sons as Authors -- 5. Fathers as Publishers -- 6. The Daughter as Author -- 7. Lovers as Authors -- 8. At Sea with the Family -- 9. Yellow News, Yellow Stories -- 10. The Return Home -- Notes -- Bibliography -- Index -- About Jay WilliamsIn Author Under Sail, Jay Williams offers the first complete literary biography of Jack London as a professional writer engaged in the labor of writing. It examines the authorial imagination in London's work, the use of imagination in both his fiction and nonfiction, and the ways he defined imagination in the creative process in his business dealings with his publishers, editors, and agents. In this first volume of a two-volume biography, Williams traverses the years 1893 to 1902, from London's "Story of a Typhoon" to The People of the Abyss. The Jack London who emerges in the pages of Author Under Sail is a writer whose partnership with publishers, most notably his productive alliance with George Brett of Macmillan, was one of the most formative in American literary history. London pioneered many author models during the heyday of realism and naturalism, blurring the boundaries of these popular genres by focusing on absorption and theatricality and the representation of the seen and unseen. London created an impassioned, sincere, and extremely personal realism unlike that of other American writers of the time. Author Under Sail is a literary tour de force that reveals the full range of London as writer, creative citizen, and entrepreneur at the same time it sheds light on the maverick side of machine-age literature.Description based on publisher supplied metadata and other sources.Electronic reproduction. Ann Arbor, Michigan : ProQuest Ebook Central, YYYY. Available via World Wide Web. Access may be limited to ProQuest Ebook Central affiliated libraries
- …
